Drug Profile
AZD 1979
Alternative Names: AZD-1979Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Obesity therapies
- Mechanism of Action Melanin-concentrating hormone receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Obesity(In volunteers) in USA (PO, Liquid)
- 28 Jul 2014 AstraZeneca terminates a phase I trial in healthy volunteers in USA after stopping criteria were reached (NCT02072993)
- 31 Mar 2014 Phase-I clinical trials in Obesity (In volunteers) in USA (PO)